Spring Bank Pharmaceuticals, Inc. (SBPH) Company Bio
Spring Bank Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of a class of therapeutics using its proprietary small molecule nucleic acid hybrid (SMNH) chemistry platform. The company was founded in 2002 and is based in Milford, Massachusetts
WILMINGTON, Del., Sept. 23, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating: Spring Bank Pharmaceuticals, Inc. (NASDAQ GS: SBPH) regarding possible breaches of fiduciary duties and other violations of law related to Spring Bank’s agreement to acquire F-star Therapeutics Limited. Under the terms of the agreement, shareholders of Spring Bank will own approximately 38.8% of the combined company and F-star Therapeutics shareholders will own approximately 61.2% of the combined company. To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-spring-bank-pharmaceuticals-inc.NTN Buzztime, Inc. (NYSE American: NTN) regarding possible breaches of fiduciary duties and other violations of law related to NTN Buzztime’s agreeme...
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Spring Bank Pharmaceuticals, Inc. ("SBPH" or the "Company") (NASDAQ: SBPH) in connection with SBPH's July 29, 2020 merger and exchange agreement with privately-held biopharmaceutical company, F-star Therapeutics Limited ("F-star"). Under the terms of the proposed transaction, SBPH will acquire the issued capital of F-star and each ordinary share of F-star in exchange for SBPH shares. Following consummation of the proposed transaction, F-star will become a publicly-listed company, with F-star holders owning 61.2% of the combined company and SBPH stockholders owning just 38.8%.
Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies: